The purpose of USP General Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations, released on June 1st, 2019, in alignment with USP <797> and <800>, is to provide minimum standards for compounded nonsterile preparations (CNSPs). Like USP <797>, USP <795> aims to ensure that pharmacy is producing the best quality products for the patient while minimizing contamination risks. The scope of USP <795> encompasses pharmacists and technicians, as well as any providers, including physicians and nurses, who manipulate CNSPs.
USP <795> Section 4, Buildings and Facilities, provides guidance regarding compliant design for the compounding space, storage area, and water sources. Ensuring that the space where CNSPs are produced is safe and compliant is the responsibility of the health-system pharmacist.
Designing the Compounding Space
USP <795> compliant CNSP compounding facilities must have a space that is specifically designed for compounding these preparations. Moreover, a visible perimeter must be in place and described in the facility’s standard operating procedure (SOP). The visible perimeter could be a different color of flooring (not carpet, which is prohibited) that underscores that this space is designated for CNSP compounding. The space must display signage that specifies that the area is for nonsterile compounding only; other activities must not occur in this space at the same time.
This location may be a separate room or simply a designated countertop. See pppmag.com/795compoundingroom for an example of a dedicated room for USP <795> compounding, separate from the USP <800> compounding room. The nonsterile compounding room may be used to produce topicals, capsules, pediatric medications, dermatological drugs, etc.
Describing the space in the SOP is critical. For example, specify if the designated USP <795> compounding space is a designated countertop with signage, or a separate room with signage. In addition, delineate where the visible perimeter is located.
When designing a compliant area, multiple issues must be considered, including workflow, surfaces, sinks and plumbing, storage, and containment.
The space must also be arranged in such a way to minimize cross-contamination from non-compounding areas. For example, if the CNSP compounding space is a specific countertop, and active pharmaceutical ingredients are being handled nearby, is there a chance that the aerosolized and micronized powders could cross-contaminate other areas? When designing a space, be cognizant of the flow of product into and out of the area to prevent errors and enable a smooth workflow.
Like USP <797> compliance, <795> compliance is necessary to ensure compounded preparations are safe and effective for patients. Ensuring the compounding space, storage area, and sink are compliant with USP <795> is critical to this pursuit.
Bryan’s webinar, USP Compliance: USP <795> Facility Requirements, is available at: pppmag.com/webinars
Bryan Prince, MBA, is a compounding workflow and lab designer, and the owner of Lab•Red Pharmacy Consultants. He has published numerous articles on compounding pharmacy workflow design and has been invited to speak at conferences on workflow and USP <800> throughout the United States and Canada.
Enter our Sweepstakes now for your chance to win the following prizes:
Just answer the following quick question for your chance to win:
Entries are limited to one entry per person in any active sweepstakes.
Thank you for your entry.